DongKoo Bio & Pharma

006620 · KOSDAQ · ₩006620 · 동구바이오제약

₩3,310▲ ₩125 (3.92%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩2,789

vs the current price (₩3,310)

Enterprise value
₩152B
Equity value
₩79B
WACC
5.9%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
—
Base
₩2,789
−15.7%
Bull
₩12,284
+271.1%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (5.2%).

Revenue growth

  • 7.6%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.6% a year, annual reports), fading to 3% by year 5.

  • 6.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.6% a year, annual reports), fading to 3% by year 5.

  • 5.3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.6% a year, annual reports), fading to 3% by year 5.

  • 4.1%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.6% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.6% a year, annual reports), fading to 3% by year 5.

Business

  • 5.2%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 2.4%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 8.7%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 17.5%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.08%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-29.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.07, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.58%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩241B
Net debt (borrowings and leases − cash and deposits)
₩72B
Shares
28,464,992
Share price
₩3,310
Market cap
₩94B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩216B₩249B₩243B₩260B₩276B₩291B₩303B₩312B
Growth10.6%15.6%−2.6%7.6%6.4%5.3%4.1%3.0%
EBIT₩15B₩13B₩9.2B₩14B₩14B₩15B₩16B₩16B
EBIT margin6.8%5.1%3.8%5.2%5.2%5.2%5.2%5.2%
After-tax EBIT₩11B₩9.2B₩6.7B₩9.8B₩10B₩11B₩11B₩12B
+ Depreciation₩4.8B₩5.5B₩6.5B₩6.2B₩6.6B₩7B₩7.3B₩7.5B
− Capital spending₩16B₩25B₩20B₩23B₩24B₩25B₩26B₩27B
− Working capital₩14B−₩3.5B₩29B₩3.2B₩2.9B₩2.6B₩2.1B₩1.6B
Free cash flow−₩14B−₩7.3B−₩36B−₩9.8B−₩9.9B−₩9.9B−₩9.8B−₩9.5B
Discount factor———0.9440.8910.8410.7940.750
Present value———−₩9.2B−₩8.8B−₩8.4B−₩7.7B−₩7.1B

Terminal value ₩257B, worth ₩193B today: 127% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩4,992 a share)Now 0.66×₩4,7400.95×₩7,5671.52×₩10,0872.02×
Price / earnings (last 12 months: ₩1,160 a share)Now 2.85×₩3,3232.87×₩23,22520.0×₩30,20826.0×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
4.9%₩3,396₩4,296₩5,501₩7,198₩9,768
5.4%₩2,424₩3,088₩3,942₩5,086₩6,696
5.9%₩1,657₩2,160₩2,789₩3,600₩4,684
6.4%₩1,038₩1,428₩1,904₩2,500₩3,268
6.9%₩529₩837₩1,206₩1,657₩2,221

Now (TTM)

Market cap
₩94B
Enterprise value
₩165B
P/E
2.9×
P/B
0.7×
P/S
0.4×
EV/EBITDA
24.8×
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩5,470₩4,800₩5,660₩6,140₩8,220
Market cap₩156B₩137B₩161B₩175B₩234B
P/E3.1×67.1×13.6×26.4×25.1×
P/B1.0×1.3×1.5×1.7×2.3×
P/S0.6×0.5×0.7×0.9×1.5×
EV/EBITDA15.9×10.2×9.3×8.1×18.3×
Dividend yield0.0%0.0%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
DongKoo Bio & Pharma2.9×0.7×0.4×24.8×0.0%
Samsung Biologics32.0×7.6×14.0×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen80.5×29.0×61.2×—0.1%
SK biopharmaceuticals14.7×5.8×6.8×—0.0%
Yuhan24.0×2.4×2.5×31.3×0.8%
HLB—15.7×55.6×—0.0%
Similar companies (median)27.9×6.7×11.5×31.3×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: DongKoo Bio & Pharma / 동구바이오제약 / 006620 / KRX:006620

Source: KRX statistical information